scholarly journals E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases

Oncogene ◽  
2010 ◽  
Vol 29 (19) ◽  
pp. 2760-2771 ◽  
Author(s):  
L Asnaghi ◽  
W C Vass ◽  
R Quadri ◽  
P M Day ◽  
X Qian ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Rho Gtpases ◽  
Small Cell ◽  
Small Cell Lung ◽  
Neoplastic Growth ◽  
E Cadherin

scholarly journals The role of E-cadherin expression in non-small cell lung cancer

2000 ◽  
Vol 15 (5) ◽  
pp. 501 ◽  
Author(s):  
Sung Chul Lim ◽  
Il Gweon Jang ◽  
Young Chul Kim ◽  
Kyung Ok Park
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
E Cadherin

scholarly journals RHO Guanine Nucleotide Exchange Factors Predict Prognosis of Non-Small Cell Lung Cancer: A Comprehensive Bioinformatics Analysis

2020 ◽  
Author(s):  
Rui-Jie Zeng ◽  
Chun-Wen Zheng ◽  
Yi-Wei Xu ◽  
Li-Yan Xu ◽  
En-Min Li
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Rho Gtpases ◽  
Bioinformatics Analysis ◽  
Expression Profiles ◽  
Small Cell ◽  
Nucleotide Exchange ◽  
Small Cell Lung

Abstract Background: Conventionally, RHO GEFs are known as activators for RHO GTPases which promote tumorigenesis. However, the role of RHO GEFs in non-small cell lung cancer (NSCLC) remains largely unknown. Methods: A comprehensive bioinformatics analysis of protein structure, transcriptional expression, survival, methylation, mutation and gene-set enrichment data was performed using multiple databases. Results: Through the screening of 81 RHO GEFs for their expression profiles and correlations with survival, four of them are identified with strong significance for predicting the prognosis of NSCLC patients. The four RHO GEFs, namely ABR, PREX1, DOCK2 and DOCK4, are downregulated in NSCLC compared to normal tissue. The downregulation of ABR, PREX1, DOCK2 and DOCK4, which can be contributed by promoter methylation, is correlated with unfavorable prognosis. Moreover, the underexpression of the four key RHO GEFs upregulates MYC signaling and DNA repair pathways, leading to carcinogenesis and poor prognosis. Conclusions: The data unveil the unprecedented role of ABR, PREX1, DOCK2 and DOCK4 as tumor suppressor in NSCLC. The previously unnoticed functions of RHO GEFs in NSCLC will inspire researchers to investigate the distinct roles of RHO GEFs in cancers, in order to provide critical strategies in clinical practice.

Prognostic role of integrin β1, E-cadherin, and rac1 expression in small cell lung cancer

Apmis ◽  
2011 ◽  
Vol 120 (1) ◽  
pp. 28-38 ◽  
Author(s):  
MYUNG HEE CHANG ◽  
KYUNGJI LEE ◽  
KYO-YOUNG LEE ◽  
YEON SIL KIM ◽  
YOUNG KYOON KIM ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Prognostic Role ◽  
Integrin Β1 ◽  
Rac1 Expression ◽  
E Cadherin

Do we Need Maintenance Chemotherapy in Advanced NSCLC in the Era of Immune and Targeted Therapy?

2019 ◽  
Vol 15 (1) ◽  
pp. 50-55
Author(s):  
Ahmed Nagy ◽  
Omar Abdel Rahman ◽  
Heba Abdullah ◽  
Ahmed Negida
Keyword(s):  
Lung Cancer ◽  
Maintenance Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Statistical Significance ◽  
Small Cell ◽  
Maintenance Chemotherapy ◽  
Small Cell Lung ◽  
The Impact

Background: Although well established for the effective management of hematologic cancers, maintenance chemotherapy has only been recently incorportated as a treatment paradigm for advanced non–small-cell lung cancer. Maintenance chemotherapy aims to prolong a clinically favorable response state achieved after finishing induction therapy which is usually predefined in number before startng treatment. There are 2 modalities for maintenance therapy; continuation maintenance (involving a non-platinum component which was a part of the induction protocol or a targeted agent) and switch maintenance therapy (utilizing a new agent which was not a part of the induction regimen). Methods: The purpose of this article is to review the role of maintenance therapy in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC) and provide a brief overview about induction chemotherapy in NSCLC to address the basis of maintenance therapy as a treatment option. We will also compare the impact of maintenance chemotherapy with the now evolving role of immunotherapy in NSCLC. Results: There have been 4 maintenance studies to date showing prolonged PFS and OS with statistical significance. However, Three out of the four studies (ECOG4599, JMEN, and PARAMOUNT) did not report tumor molecular analysis. As regard Immunotherapy, current data is in favour of strongly an increasing role for immunotherapy in NSCLC. Conclusion: Maintenance therapy in NSCLC continues to be an important therapeutic line to improve outcome in patients with metastatic and recurrent disease.

scholarly journals P09.25 Role of Immune Checkpoint Inhibitors (ICPi) in KRAS-Mutated Non-Small Cell Lung Cancer (NSCLC)

2021 ◽  
Vol 16 (3) ◽  
pp. S300-S301
Author(s):  
M. Peravali ◽  
C. Gomes-Lima ◽  
E. Tefera ◽  
M. Baker ◽  
M. Sherchan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals MA12.04 Should the Role of Surgery Be Re-Evaluated in Small Cell Lung Cancer?

2021 ◽  
Vol 16 (3) ◽  
pp. S177-S178
Author(s):  
S. Ricciardi ◽  
F. Davini ◽  
G. Ali ◽  
C. Zirafa ◽  
G. Romano ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document